on Y chromosome (GBY) and azoospermia factor (AZF) (Figure 1) . The SRY gene has been demonstrated to be the testis-determining gene, 24, 25 while a group of genes, that is, RBMY and DAZ, have been identified within the AZF locus on the long-arm. 15, 26, 27 The gonadoblastoma (GBY) locus was initially mapped to a small region on the short arm of the Y chromosome proximal to the centromere, harboring a gene predisposing dysgenetic gonads of XY sex-reversed patients to develop gonadoblastoma. 28 Subsequent studies showed that TSPY is the putative gene for this locus. 29 , 30 The sex determination and genes for the AZF locus have recently been reviewed in details. 27, 31, 32 The present review focuses on the MSY genes and their associations to human tumors, including gonadoblastoma.
EXPRESSION OF Y-LINKED GENES AND HUMAN CANCERS
Various studies have demonstrated that TSPY and RBMY are ectopically expressed in somatic cells under disease conditions, such as cancer, although they are normally expressed preferentially in testicular germ cells (see below). To explore the changes of MSY genes in somatic cancers, we had performed a data-mining study on hepatocellular carcinoma (HCC) using the RNA-Seq gene expression data on 27 pairs of male tumor-nontumor paired samples at the Cancer Genome Atlas (TCGA) project. 33 Our results showed that, in addition to TSPY and RBMY, other MSY genes, that is, TGIF2LY and VCY, were consistently up-regulated in ~30% cases of liver cancer, while DDX3Y, ZFY, and DAZ1 were frequently down-regulated (~70%, Figure 2 ). Since the Y chromosome is unique to men, these observations suggest that the Y chromosome genes could potentially influence on the development, progression and outcomes of liver cancer in a male-specific manner(s).
Testis-specific protein, Y-encoded (TSPY)
The human TSPY gene was initially identified as a Y-linked gene specifically expressed in the testis. 34, 35 It is tandemly repeated in 20.3-kb highly homologous units, usually in the range of 21-35 copies, on the short arm of the Y chromosome. 15, [36] [37] [38] The human TSPY is expressed in gonocytes in the embryonic testis, 39 spermatogonia, and prophase I spermatocytes at preleptotene to zygotene stages in adult testis. 40 Deletion mapping has localized the TSPY repeat units to the critical region harboring the GBY locus on the short arm. 29, 30 It is postulated to serve normal functions in male germ cell differentiation, mitosis, and meiosis, 41, 42 but could promote gonadoblastoma development in patients with disorders of sex developments (DSDs) harboring Y chromosome materials including TSPY. Indeed, TSPY expression has been observed in gonadoblastoma, and various types of germ cell tumors (GCTs), including carcinoma in situ/intratubular germ cell neoplasia unclassified (CIS/ITGCNU) (the precursor for all testicular GCTs [TGCTs]), seminoma, and extragonadal intracranial GCT. [43] [44] [45] [46] In addition to GCTs, TSPY is frequently expressed in some somatic cancers including liver cancer, 47, 48 melanoma, 49 and prostate cancer, 50, 51 suggesting that TSPY can be considered as a cancer-testis antigen (CT-antigen). CT-antigens are group of proteins that are predominantly/specifically in testis under normal conditions, but are ectopically expressed in somatic cancers. 52 Although the biological functions of CT-antigens are currently uncertain, they have been proposed as diagnostic markers and therapeutic targets in cancers. 48, [52] [53] [54] Molecular functions of TSPY TSPY is a member of SE translocation/nucleosome assembly protein 1 (SET/NAP1) superfamily harboring a highly homologous SET/ NAP-domain, initially identified in the SET oncoprotein (also called template-activating factor I or TAF-I) and the NAP1. 42, 55 X-ray crystallography showed that the SET protein forms a homodimer with a headphone like structure, and the SET/NAP domain occupies the earmuff region, which could be important for protein-protein binding with interactive partners. The N-terminal alpha-helix region contains the binding site for the homodimerization. [56] [57] [58] Members of the SET/NAP1 protein family could function as chaperones of histones. In particular, NAP1 plays crucial roles in shuttling and assembling core histones as a histone chaperone. 57, 59 SET forms inhibitor of histone acetyltransferase (INHAT) complex with its isoform TAF-Iα and pp32. 60 INHAT complex associates with chromatin to inhibit the histone acetylation mediated by acetyltransferases, thereby suppressing the expression of targeted genes. 60 SET also interacts with transactivators and enhances their respective target gene expression. 54, 61 These observations suggest that SET/NAP1 proteins serve a wide range of functions in many biological processes. Recently, we reported that TSPY binds the type B cyclins and enhances the kinase activity of the cyclin-B/CDK1 complex. 62 Correlating with this function, overexpression of TSPY leads to shortening of the G2/M phase and acceleration of cell proliferation in TSPY-transfected HeLa and 3T3 cells in vitro and tumorigenicity in athymic mice in vivo. 63 In contrast, its single-copy X-linked homolog TSPX (also termed as TSPY-like 2 [TSPYL2], differentially expressed nuclear TGF-β1 target [DENTT] or cell division autoantigen 1 [CDA1]) inhibits the kinase activity of cyclin-B/CDK1 complex. 62 TSPX protein harbors a 250 amino acids aspartic acid/glutamic acid (D/E)-rich domain at its C-terminus, which is absent in TSPY. The inhibitory function of TSPX has been mapped on the C-terminal D/E-rich domain. 62 Since the SET/NAP-domains of both proteins are well conserved, TSPY and TSPX could play contrasting roles on their common target molecules. Abrogated TSPX expression in lung cancer is associated with accelerated cancer progression. 64 In vitro studies also demonstrated that overexpression of TSPX retards cell proliferation. 65 Further, down-regulation of TSPX by nitric-oxide correlates with the glioma stem cell proliferation. 66 These observations suggest that while TSPY and TSPX originated from the same ancestor gene, they have respectively evolved into two independent genes on the sex chromosomes, and play contrasting roles in human oncogenesis, that is, TSPY as a proto-oncogene and TSPX as a tumor suppressor gene. 67, 68 Yeast-two hybrid screening using the SET/NAP-domain of TSPY as bait has identified several novel TSPY binding proteins. The first one is the translation elongation factor 1A, eEF1A. The SET/NAP domain of TSPY binds to the domain-III of eEF1A, and enhances protein synthesis. 69 TSPY also binds to the 40S ribosomal component RPS26 (unpublished data), suggesting that TSPY could be associated with the protein synthesis machinery in the cells. Recent studies suggest that protein synthesis is crucial in the regulation of cell proliferation and cancer progression. [70] [71] [72] [73] TSPY may normally support protein synthesis essential for the maintenance of germ cell proliferation, but when ectopically expressed, it could promote cancer growth under diseased conditions. Interestingly, we also showed that TSPY protein binds to the exon-1 of its structural gene and enhances its own expression in prostate cancer cells, 74 suggesting that TSPY could intensify its functions by amplifying its own gene expression through a positive feedback loop. Hence, TSPY could play the role of a transcription regulator, by binding to the DNA/nuclear proteins on the chromatin of target genes. Since TSPY is located in the male-only Y chromosome, its functions in the protein synthetic machinery, cell cycle progression, histone chaperone/chromatin modification gene, and regulation could shed new insights on sex disparities associated with the development, progression and treatments responses among numerous somatic cancers, e.g., liver cancer and melanoma, with ectopic TSPY expression.
Expression of TSPY in germ cell tumors
Human GCTs can be classified into five types based on various parameters including age at clinical presentation, anatomical sites and histology; e.g., type-I, teratoma/yolk sac tumor; type-II, seminomatous/nonseminomatous GCTs; type-III, spermatocytic seminoma; type-IV, dermoid cyst; type-V, hydatidiform mole. 75 TSPY expression is primarily detected in type-II TGCs and type-III spermatocytic seminoma. 44 Type-II TCGs are further subdivided into nonseminomatous GCTs and seminomatous GCTs, including seminoma, dysgerminoma, germinoma, and gonadoblastoma.
75, 76 The type-II testicular germ cell tumors (TGCTs) are the most common malignancies among young men aged 15 to 34 years in United States, and its incidence is approximately 1.38-6.31 per 100 000 (years of 1973 to 2001). 77 The incidence of TGCTs is globally increased during the past 70 years, especially among men of European ancestry, and the etiologies of such preference are uncertain. 78, 79 TGCTs, both seminoma and nonseminoma, are derived from CIS/ ITGCNU. 75, 76, 80, 81 CIS/ITGCNU cells display a close phenotype to fetal germ cells, suggesting their origin is due to a developmental delay or failure of differentiation of early germ cells (Figure 3) . 75, [82] [83] [84] TSPY is expressed in gonocytes 85 and most CIS/ITGCNU cells with some minor exceptions (Figure 3) . 43, 44 Upon further oncogenic progression, the seminoma cells maintain TSPY expression while, nonseminoma cells do not or rarely express TSPY (Figure 3) . 43, 44, 86 It has been speculated that the development of nonseminoma TGCT requires reprogramming to embryonic carcinoma state. 75 Indeed, the global gene expression analysis using microarray hybridization strategy indicated that embryonic carcinoma cells showed significant similarities with human embryonic stem cells, while seminoma closely resemble transformed primordial germ cells. 87 Accordingly, TSPY expression likely correlates with the germ cell lineage even in maturation-disturbed germ cells, but not with the reprogrammed cells like embryonic carcinoma with acquired pluripotency.
Gonadoblastoma is a subclass of type-II TCGs preferentially developed in the dysgenetic gonads of XY females or individuals with DSD. 75, 76, 88 The Y chromosome of gonadoblastoma patients frequently lacks sex determination region but retains common region of the short arm, termed GBY locus. [28] [29] [30] The tandemly repeated units of TSPY gene are mapped within GBY critical region on the Y chromosome, hence TSPY is considered as a candidate gene for GBY, promoting gonadoblastoma development in the dysgenetic gonads of DSD patients. [28] [29] [30] Gonadoblastoma morphologically resembles the CIS/ITGCNU in the TGCTs in the testis; gonadoblastoma cells are mixed with granulosa-like cells while TGCT cells are mixed with Sertoli cells in the seminiferous tubules enclosed by myoid cells. 89 Most OCT4-positive gonadoblastoma cells strongly express TSPY as well as the germ cell/placental alkaline phosphatase (PLAP) and the proto-oncogene receptor c-Kit, similar to the testicular CIS. 43, 45, 86, 88 Noticeably, TSPY is rarely expressed in the dysgerminoma after progression from gonadoblastoma. 86, 88 Dysgerminoma is considered as a counterpart of seminoma based on morphology and expressed biomarkers. [90] [91] [92] Loss of TSPY expression in dysgerminoma may indicate the dividing characteristics between dysgerminoma and seminoma.
Overall, TSPY is expressed differentially in a subset of GCTs positive for both OCT4 and PLAP biomarkers. Since TSPY is most frequently expressed in the CIS and gonadoblastoma, at early stages of germ cell tumorigenesis, it is postulated to play an important role in early stages of oncogenesis in the immature germ cell lineage. Accordingly, the risk of GCT development/progression is higher in TSPY positive than TSPY negative cases. 93 TSPY could accelerate such progression of GCTs through its functions in cell cycle, protein synthesis, and histone/chromatin modification and gene regulation, as discussed above.
Expression of TSPY in somatic cancers
In addition to type-II and III GCTs, ectopic expression of TSPY has been frequently detected in various types of somatic cancers, including HCC, 47, 48 melanoma, 49 and prostate cancer. 50, 51 Yin et al. 48 reported that TSPY expression was detected in 50% cases of early stage HCC and 16% cases in undifferentiated stage (later stage of HCC). Our recent studies also demonstrated that TSPY was detected in 19.2% cases in tissue microarray and 46.9% cases in RNA samples isolated from fresh HCC specimens. 47 Further immunohistochemical analysis showed that TSPY is expressed in the glypican 3-positive cells, a biomarker of the HCC. 47, 94 In the studies of prostate cancer, TSPY was immunohistochemically detected in the regions positive for alpha-methylacyl-CoA racemase, a biomarker of prostatic intraepithelial neoplasia and prostate cancer cells. 50, 95 TSPY expression was more frequently detected in clinical prostate cancer specimens (78%) than latent prostate cancer (47%) and noncancer prostate tissues (50%). 50 These observations clearly indicate that TSPY is ectopically activated in somatic cancer cells.
While the correlation between TSPY expression and clinical outcome is still unclear, TSPY has been suggested as a prognostic biomarker and therapeutic target for immunotherapy. 48 Further analysis incorporating clinical outcomes and TSPY expression would be important to elucidate the significance of TSPY expression on cancer progression and immunotherapy.
Rodent Tspy and human TSPY transgenic mouse models
Although TSPY is an evolutionarily conserved gene on the Y chromosomes of mammals including apes and bovines, 96, 97 the mouse Tspy gene is apparently nonfunctional as it contains multiple in-frame stop codons within the open reading frame. 98 Rat Y chromosome harbors a single functional copy of Tspy gene, 99 but its expression pattern is different from human TSPY, that is, the rat Tspy is expressed only in elongating spermatids while the human TSPY is primarily expressed in spermatogonia and spermatocytes, 100 suggesting that the biological functions of the rat Tspy could be different from those of human TSPY. Accordingly, the gene knockout in rodents might not be a suitable strategy to explore the biological functions of human TSPY. To overcome this difficulty, Schubert et al. 101 had generated a transgenic mouse line harboring 50 copies of human TSPY gene on Y chromosome of the mouse, designated as TgTSPY9. The 8.2-kb transgene contains 2.95-kb the promoter region, 2.8-kb structural gene and 2.45-kb 3' flanking sequence of the human TSPY gene. It is predominantly expressed in spermatogonia and spermatocytes at early stages of spermatogenesis, similar to the pattern of TSPY in human testis. 101 Expression of human TSPY transgene in testicular germ cells of TgTSPY9 mice does not show any significant effects in fertility or other physiology, 101 consistent with the observation that the copy number of human TSPY gene varies among fertile men. 38 By introducing the Y-located TSPY transgene of TgTSPY9 to the LADY mouse model of prostate cancer, we have demonstrated that the Y-located TSPY could be aberrantly activated during oncogenesis in the LADY model of prostate cancer. 102 However, while TSPY is expressed in FoxA1-positive epithelial cells and prostate cancer cells in human clinical prostate cancer specimens, TgTSPY9 transgene was expressed in FoxA1-negative hypercellular stroma areas in the prostate of LADY mice. 102 Such differential expression patterns suggest the potential limitations of current mouse models of prostate cancer in mimicking the ectopic expression of TSPY under disease conditions, such as during prostate cancer development.
Azoospermia factor (AZF) genes and cancer
RNA-binding motif protein, Y-linked (RBMY) isoforms are encoded by repetitive genes within the AZF region, frequently deleted in azoospermia patients (Figure 1) . RBMY binds to the RNA stem-loops capped by a C[A/U] CAA pentaloop 103 and may participate in the alternative splicing of various testis-specific gene transcripts. 104 Indeed, deletion of RBMY resulted in the failure of meiosis. 105 Abnormal expression of RBMY was observed in 36% cases of male liver HCC but not in normal liver tissues. 106, 107 Over-expression of RBMY caused tumorigenicity in mouse fibroblast 3T3 cells, 106 and knock-down of RBMY in a liver cancer cell line HepG2 resulted in the reduction of transformation and anti-apoptotic efficiencies. 107 Further, the liver-specific RBMY transgenic mice showed accelerated hepatic neoplastic changes in the diethylnitrosamine-induced hepatocarcinogenesis animal model. 107 While the mechanism is still unclear, these observations suggest that the ectopic expression of RBMY genes could contribute to HCC development. On the contrary, multiple copies of BPY2, DAZ, and CDY1 genes are also mapped onto the microdeletion of AZFc region, and deletions of these AZF genes are associated with increased risks of seminoma. 108, 109 Consistently with these reports, our analysis of TCGA data showed that DAZ1 and BPY2 are frequently down-regulated in HCC (Figure 2) . Although these observations are preliminary in nature, further studies on AZF genes could provide new insights into the roles of Y chromosome in cancer development and their usefulness as diagnostic biomarkers.
CONCLUSIONS AND FUTURE ASPECTS
In the past decades, associations between MSY genes and diseases have been identified. However, because of differences between human and rodents Y chromosomes 21, 110 and difficulties in generating knockout mice of Y chromosome genes, 111 there are still limitations on investigating the roles of human MSY genes in vivo. As it has been suggested, most MSY genes may function as broadly expressed regulators for gene expression, protein stability and maintenance of the dosage of homologous XY gene pairs. 21 Supporting this hypothesis, it was demonstrated that UTX and UTY could play comprehensive, but independent of their demethylase activities, during embryonic development. 112 On the other hand, while TSPY displays proto-oncogenic properties, 62,63,69 its X-linked homolog TSPX is a tumor suppressor and down-regulated in cancer. 62, 65, 66 This is the first example for an MSY gene and its X-homologue possess distinct and opposing functions. Hence, it is important to establish respective in vivo models to elucidate the roles of human MSY genes in development and progression of diseases, including cancers.
Recently, an epidemiologic study reported that loss of Y chromosome (LOY) in peripheral blood cells significantly associated with shorter cancer survival and higher risk of cancer incidence in men. 113 LOY in peripheral blood is frequently observed in elder men. 114 According to a clinical study with >40 years of follow-up, Forsberg et al. found that LOY in peripheral blood associated with increased risk of both all-caused mortality and cancer mortality, particularly in nonhematological cancers. 113 Further, transcriptome analysis of human peripheral blood samples detected the expression of some Y chromosome genes, e.g., EIF1AY, DDX3Y, KDM5D, CYorf15B, CYorf15A, and UTY. 115 Although the mechanism linking LOY in human peripheral blood and cancer mortality remains to be elucidated, these observations strongly suggest that Y chromosome genes are involved in a wide variety biological processes that have not been fully explored. MSY genes play crucial roles in both hormonal regulation and the balance in gene expression and protein stability, as described above. Ectopic expression of one or a few of these Y chromosome genes, such as TSPY and RBMY, could exacerbate oncogenesis in the absence of proper counter-balance from the other MSY genes (Figure 4) . Further studies of Y chromosome genes from the global aspects, including both coding and noncoding RNA genes, will shed new lights on their roles in health and diseases in men.
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